EGFR and nasopharyngeal carcinoma: Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors have been proven to efficiently inhibit the proliferation of cancers, especially colorectal and nasopharyngeal cancers [8]; [9].